Next Article in Journal
Establishment of a Suspension MDBK Cell Line in Serum-Free Medium for Production of Bovine Alphaherpesvirus-1
Previous Article in Journal
Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention
 
 
Review
Peer-Review Record

Current Progress in the Development of Zika Virus Vaccines

Vaccines 2021, 9(9), 1004; https://doi.org/10.3390/vaccines9091004
by Kehui Zhou 1,†, Chaoqun Li 1,†, Wen Shi 1, Xiaodan Hu 1, Kutty Selva Nandakumar 2,*, Shibo Jiang 3,* and Naru Zhang 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Vaccines 2021, 9(9), 1004; https://doi.org/10.3390/vaccines9091004
Submission received: 22 August 2021 / Revised: 4 September 2021 / Accepted: 7 September 2021 / Published: 9 September 2021

Round 1

Reviewer 1 Report

This review article drafted by Kehui Zhou et al. covers most of the advances in Zika virus vaccine development. This review article has appropriately cited all the research articles in the field and summarized the findings. Below are the reviewer’s comments.

It will be useful if the authors would have generated a table to compare and contrast different types of vaccines. Though it would be a common feature of the vaccines and can be found elsewhere, still generating a concise table in this review will be valuable to the reader.

All the tables also indicate the dose of vaccines, virus challenges, route of vaccine administration using a separate column for each.      

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

This is a well-structured and useful review wit up to date references. I have a few minor comments and questions for the authors to address:

  1. Abstract line 1 'occult' is an unusual term- insidious might be better
  2. Abstract line 45 -keep to present tense, so 'discussed' should be 'discuss'
  3. line 41 Introduction- please reference the statement about common epitopes between Dengue and Zika -is it reference[10]?
  4. Line 59 -present tense, therefore 'summarise' and 'discuss'
  5. Line122  -what is CoVaccine HT? also 10mg seems like a very high dose?
  6. line 180- 'focus-forming units' seems an unusual term; should this be plaque-forming units?
  7. line 185-what is the route of delivery with the novel Tri-Grid?
  8. Table 4: what is meant by 'suitable levels' of protective response?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop